^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MUC16 inhibitor

    Related drugs:
    5d
    NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers. (PubMed, BMC Cancer)
    Tumor-produced CA125 impairs therapeutic antibody and ADC efficacy via humoral immunosuppression. NAV-005 counteracts this effect, restoring antitumor activity of antibodies and ADCs in CA125-expressing cancers. These results support the continued development of CA125 antagonists as adjuncts to antibody-based cancer therapies.
    Journal
    |
    MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    13d
    RegeNovar: Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=43, Not yet recruiting, ARCAGY/ GINECO GROUP
    New P1/2 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated) • CD4 (CD4 Molecule)
    |
    HRD
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • ubamatamab (REGN4018)
    17d
    Gineco-ov133b: REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy. (2025-524232-20-00)
    P1/2, N=43, Not yet recruiting, Asso De Recherche Cancers Gynecologiques
    New P1/2 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • ubamatamab (REGN4018) • Neupogen (filgrastim)
    1m
    A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=26, Completed, Nanjing Leads Biolabs Co.,Ltd | Recruiting --> Completed | N=468 --> 26
    Trial completion • Enrollment change
    |
    LBL-033
    2ms
    R4018-ONC-1721: Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (clinicaltrials.gov)
    P1/2, N=890, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Feb 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Libtayo (cemiplimab-rwlc) • Actemra IV (tocilizumab) • ubamatamab (REGN4018) • Kevzara (sarilumab)
    3ms
    Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, CanariaBio Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Apr 2024 --> Oct 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • OvaRex (oregovomab)
    3ms
    QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, CanariaBio Inc. | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Zejula (niraparib) • OvaRex (oregovomab)
    3ms
    FLORA-4: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov)
    P3, N=615, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    3ms
    QPT-ORE-006: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Jan 2026 --> Oct 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    3ms
    Compassionate Use of Ubamatamab (clinicaltrials.gov)
    P=N/A, N=0, Available, Regeneron Pharmaceuticals
    New trial
    |
    ubamatamab (REGN4018)
    3ms
    A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=300, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    ubamatamab (REGN4018) • Kevzara (sarilumab)
    8ms
    A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer. (PubMed, Curr Oncol)
    The safety and compatibility of combining oregovomab with Hiltonol® have been demonstrated in this study. The potential to enhance activity of chemotherapy using oregovomab indirect immunization and Hiltonol® stimulation is proposed.
    P1 data • Journal • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated) • TLR3 (Toll Like Receptor 3)
    |
    Hiltonol (poly-ICLC) • OvaRex (oregovomab)